PT935609E - Composicoes cristalizaveis que contem um complexo entre o dominio de protease ns3 do virus da hepatite c e ns4a cristais resultantes - Google Patents

Composicoes cristalizaveis que contem um complexo entre o dominio de protease ns3 do virus da hepatite c e ns4a cristais resultantes

Info

Publication number
PT935609E
PT935609E PT97942450T PT97942450T PT935609E PT 935609 E PT935609 E PT 935609E PT 97942450 T PT97942450 T PT 97942450T PT 97942450 T PT97942450 T PT 97942450T PT 935609 E PT935609 E PT 935609E
Authority
PT
Portugal
Prior art keywords
hepatitis
complex
ns4a
protease
virus
Prior art date
Application number
PT97942450T
Other languages
English (en)
Inventor
Joseph L Kim
Kurt A Morgenstern
Chao Lin
Ted Fox
John A Thomson
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of PT935609E publication Critical patent/PT935609E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C30B29/58—Macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
PT97942450T 1996-09-12 1997-09-12 Composicoes cristalizaveis que contem um complexo entre o dominio de protease ns3 do virus da hepatite c e ns4a cristais resultantes PT935609E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2527496P 1996-09-12 1996-09-12
US08/731,336 US6153579A (en) 1996-09-12 1996-10-18 Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex

Publications (1)

Publication Number Publication Date
PT935609E true PT935609E (pt) 2002-09-30

Family

ID=26699520

Family Applications (2)

Application Number Title Priority Date Filing Date
PT97942450T PT935609E (pt) 1996-09-12 1997-09-12 Composicoes cristalizaveis que contem um complexo entre o dominio de protease ns3 do virus da hepatite c e ns4a cristais resultantes
PT01101009T PT1118619E (pt) 1996-09-12 1997-09-12 Metodo para identificar agentes activos contra o vhc utilizando as coordenadas estruturais da protease do virus da hepatite c

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT01101009T PT1118619E (pt) 1996-09-12 1997-09-12 Metodo para identificar agentes activos contra o vhc utilizando as coordenadas estruturais da protease do virus da hepatite c

Country Status (13)

Country Link
US (2) US6153579A (pt)
EP (1) EP0935609B1 (pt)
JP (1) JP2001501602A (pt)
AT (3) ATE216400T1 (pt)
AU (1) AU736857B2 (pt)
CA (1) CA2264964A1 (pt)
DE (3) DE69736995T2 (pt)
DK (1) DK0935609T3 (pt)
ES (2) ES2175462T3 (pt)
HK (2) HK1022700A1 (pt)
IL (1) IL128826A0 (pt)
PT (2) PT935609E (pt)
WO (1) WO1998011134A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4080541B2 (ja) 1996-10-18 2008-04-23 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼの阻害因子
IL143798A0 (en) 1999-01-08 2002-04-21 Bristol Myers Squibb Co Hepatitis c virus ns3 protease
US6524589B1 (en) * 1999-04-08 2003-02-25 Schering Corporation Compositions of hepatitis C virus NS3/NS4A complex and methods for crystallizing same
JP2003511467A (ja) 1999-10-14 2003-03-25 ブリストル−マイヤーズ スクイブ カンパニー アンドロゲンレセプターリガンド結合ドメインの結晶構造
US7491808B2 (en) 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
HUP0600776A2 (en) 2000-11-14 2007-01-29 Bristol Myers Squibb Co A human serpin secreted from lymphoid cells lsi-01
AU2002303218A1 (en) 2001-04-03 2002-11-11 Bristol-Myers Squibb Company Polynucleotide encoding a novel cysteine protease of the calpain superfamily, can-12, and variants thereof
US20030027315A1 (en) * 2001-09-24 2003-02-06 Ada Yonath Methods of growing crystals of free and antibiotic complexed large ribosomal subunits, and methods of rationally designing or identifying antibiotics using structure coordinate data derived from such crystals
US20050009877A1 (en) * 2003-05-15 2005-01-13 Henry Lu Methods of identifying HCV NS5B polymerase inhibitors and their uses
TW201127828A (en) 2003-09-05 2011-08-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
KR20060120166A (ko) 2003-10-27 2006-11-24 버텍스 파마슈티칼스 인코포레이티드 Ｈｃｖ ｎｓ３－ｎｓ４ａ 단백질분해효소 저항성 돌연변이
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
EP1951748B1 (en) 2005-11-11 2013-07-24 Vertex Pharmaceuticals, Inc. Hepatitis c virus variants
JP5436864B2 (ja) 2006-02-27 2014-03-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｖｘ−９５０を含む共結晶体およびそれを含む医薬組成物
EP1993994A2 (en) * 2006-03-16 2008-11-26 Vertex Pharmceuticals Incorporated Deuterated hepatitis c protease inhibitors
US8440443B1 (en) 2006-05-16 2013-05-14 Merck Sharp & Dohme Corp. MEK1 polypeptides
ES2379905T3 (es) 2007-02-27 2012-05-04 Vertex Pharmceuticals Incorporated Co-cristales y composiciones farmacéuticas que los comprenden
NZ579295A (en) 2007-02-27 2012-03-30 Vertex Pharma Inhibitors of serine proteases
CL2008002549A1 (es) 2007-08-30 2010-09-03 Vertex Pharma Cocristal que comprende vx-950 y un formador de cocristal seleccionado de acido 3-metoxi-4hidroxibenzoico,acido 2,4-dihidroxibenzoico y acido 2,5-dihidroxibenzoico; metodo de preparacion; composicion farmaceutica que comprende el cocristal, util como agente antiviral en el tratamiento del hcv.
US8988881B2 (en) * 2007-12-18 2015-03-24 Sandia Corporation Heat exchanger device and method for heat removal or transfer
US9005417B1 (en) 2008-10-01 2015-04-14 Sandia Corporation Devices, systems, and methods for microscale isoelectric fractionation
US9795961B1 (en) 2010-07-08 2017-10-24 National Technology & Engineering Solutions Of Sandia, Llc Devices, systems, and methods for detecting nucleic acids using sedimentation
WO2012118982A2 (en) 2011-03-02 2012-09-07 Sandia Corporation Axial flow heat exchanger devices and methods for heat transfer using axial flow devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
US5353236A (en) * 1992-04-23 1994-10-04 The Board Of Trustees Of The Leland Stanford University High-resolution crystallographic modelling of a macromolecule
US5453937A (en) * 1993-04-28 1995-09-26 Immunex Corporation Method and system for protein modeling
IT1272179B (it) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.

Also Published As

Publication number Publication date
EP0935609B1 (en) 2002-04-17
AU736857B2 (en) 2001-08-02
DE69723485D1 (de) 2003-08-14
DK0935609T3 (da) 2002-07-22
ES2202228T3 (es) 2004-04-01
PT1118619E (pt) 2003-11-28
ATE216400T1 (de) 2002-05-15
EP0935609A1 (en) 1999-08-18
HK1022700A1 (en) 2000-08-18
DE69723485T2 (de) 2004-05-27
IL128826A0 (en) 2000-01-31
DE69736995D1 (de) 2007-01-04
ATE244729T1 (de) 2003-07-15
DE69736995T2 (de) 2007-09-20
US6153579A (en) 2000-11-28
HK1038573A1 (en) 2002-03-22
DE69712085D1 (de) 2002-05-23
JP2001501602A (ja) 2001-02-06
US6303287B1 (en) 2001-10-16
ATE346088T1 (de) 2006-12-15
WO1998011134A1 (en) 1998-03-19
AU4414597A (en) 1998-04-02
ES2175462T3 (es) 2002-11-16
DE69712085T2 (de) 2002-11-28
CA2264964A1 (en) 1998-03-19

Similar Documents

Publication Publication Date Title
PT935609E (pt) Composicoes cristalizaveis que contem um complexo entre o dominio de protease ns3 do virus da hepatite c e ns4a cristais resultantes
BG103392A (en) Serine protease inhibitors, in particular of hepatitis with virus ns3 protease
DE60144145D1 (de) Subtilisin-variante
DK0600992T3 (da) Anvendelse af gentissyre eller gentisylalkohol til stabilisering af radiomærkede peptider og proteiner
NZ504114A (en) Vitamin k-dependent polypeptides such as protein C where substitution at amino acid sites 11, 12, 29, 33 or 34 affects membrane binding affinity of the protein and ultimately blood clotting ability
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
FI946066A (fi) Hepatiitti-C viruksen genotyyppien uudet sekvenssit ja niiden käyttö terapeuttisina ja diagnostisina aineina
ITRM940092A0 (it) Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
FI935808A (fi) Hepatit-C-virus (HCV) polypeptider
DK0996409T3 (da) Præparat til at forsinke hårvækst og tilsvarende anvendelse
ES2165269A1 (es) Derivados de alfa-cetoamidas.
PT698216E (pt) Metodos de tipificacao do virus da hepatite c e reagentes para utilizar nestes
FI943724A0 (fi) Stabiloidut radiofarmaseuttiset pakkaukset
ATE131066T1 (de) Mittel zur hemmung von hiv-proteasen.
DK1276763T3 (da) Anti-fryseproteiner, deres fremstilling og anvendelse
DE69928064D1 (de) Mimotopen der hypervariabele region des e2 glykoproteins von hcv und deren verwendungen
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
FI923020A0 (fi) Inte a inte b-sekvenser.
AU2002317474A1 (en) Human recombinant antibody against the hepatitis c (hcv) non structural ns3 protein, nucleic acid and uses thereof
DE3873273D1 (de) Verfahren zur selektiven spaltung von fusionsproteinen.
EA200001252A1 (ru) КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА-β-1A(IFN-β-1A) ЧЕЛОВЕКА
ATE195322T1 (de) Verwendung von oberflächenaktiven substanzen zur stabilisierung von peptiden und proteinen zur radiopharmazeutischen verwendung
MXPA03006454A (es) Utilizacion de virus para detectar o purificar proteinas.
IT1270941B (it) Peptidi di hcv e loro usi.
SE9203159D0 (sv) Partikel suspension